Maruho Co.

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, Maruho Co. sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials none currently recruiting 10 completed top decile by trial count

Maruho Co.: 10 sponsored US clinical trials, none currently recruiting.

Maruho Co. sponsors 10 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 10 completed. 5 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acne Vulgaris, with 1 trials.

Top-decile sponsor footprint

Maruho Co. ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

A 90/100

10 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

10 total, page 1 of 1

COMPLETED Phase 3

A Study to Evaluate the Safety and Efficacy of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts

NCT03259620
COMPLETED Phase 3

A Phase 3 Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts

NCT02971891
COMPLETED Phase 3

Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle

NCT02547441
COMPLETED Phase 3

Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical Gel

NCT02576847
COMPLETED Phase 2

A Study to Evaluate the Safety and Efficacy of Omiganan (CLS001) Topical Gel Versus Vehicle in Female Subjects With Moderate to Severe Acne Vulgaris

NCT02571998
COMPLETED Phase 3

Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle

NCT02576860
COMPLETED Phase 2

Safety and Efficacy Study of CLS001Topical Gel Compared to Vehicle in Subjects With Inflammatory Acne Vulgaris

NCT02066545
COMPLETED Phase 1

A 21 Day Pharmacokinetics Study in Papulopustular Rosacea

NCT02028286
COMPLETED Phase 2

A Twelve Week Safety and Efficacy Study in Rosacea

NCT01784133
COMPLETED Phase 2

Study to Investigate the Efficacy and the Safety of M518101 in Plaque Psoriasis Patients

NCT01301157

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 4
Phase 3 5

Therapeutic Areas

Acne Vulgaris 1
Rosacea 1
Papulopustular Rosacea 1

How the Maruho Co. archive is shaped

10 indexed studies, none listed as recruiting (0% open); 10 completed (100%).

Phase mix: 5 late (III/IV) vs 5 early (I/II) (balanced across stages).

Top condition: Acne Vulgaris (1 trial), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Maruho Co.: archived-pipeline peers nationwide

Peers matched on 10 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Maruho Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Maruho Co.Adamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron Pharmaceuticals10xBio22nd Century Group23andMe3-C Institute for Social Development
Maruho Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Maruho Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Maruho Co. page

10 registered trials is a research-attention snapshot, not an endorsement of Maruho Co. or any single study.

  • None of Maruho Co.'s trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Acne Vulgaris is the condition Maruho Co. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acne Vulgaris trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Maruho Co. pipeline card: 10 registered trials from official public datasets.Report a data error.